Clinical Scorecard: Association of Abnormal Nerve Conduction Velocity Patterns with Clinical Severity in Chemotherapy-Induced Peripheral Neuropathy: A Retrospective Cohort Analysis

At a Glance

Key Highlights

• Sural SNAP amplitude inversely correlates with CIPN severity (r = −0.724, P < 0.001).
• Absolute end-of-treatment sural SNAP amplitude identifies Grade ≥2 CIPN with AUC of 0.856.
• Patients needing dose modification show larger early sural SNAP reductions (34.8% vs. 17.6%, P < 0.001).
• Four electrophysiological phenotypes associated with clinical severity and recovery trajectories were identified.

Guideline-Based Recommendations

Diagnosis

• Use nerve conduction studies (NCS) for objective assessment of peripheral nerve function.

Management

• Monitor sural SNAP amplitude and its percentage change from baseline for treatment tolerance.

Monitoring & Follow-up

• Conduct serial clinical and electrophysiological assessments at baseline, mid-treatment, end-of-treatment, and follow-up.

Risks

• CIPN can necessitate dose modifications or premature discontinuation of chemotherapy.

Patient & Prescribing Data

Patients receiving neurotoxic chemotherapy agents, including taxanes and platinum-based compounds.

Electrophysiological findings can precede clinical symptom onset in CIPN.

Clinical Best Practices

• Utilize NCS as a gold standard for diagnosing peripheral neuropathies.
• Assess both objective electrophysiological measures and clinical severity assessments for comprehensive evaluation.

Related Resources & Content

• NCI-CTCAE